Fig. 2: UGT2B17 localisation in prostate tumours. | British Journal of Cancer

Fig. 2: UGT2B17 localisation in prostate tumours.

From: Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression

Fig. 2

Immunohistochemistry staining using the EL-2B17mAb was performed on primary tumours (a–f). UGT2B17 expression in tumours is observed in both cytoplasmic and nuclear/perinuclear compartments. Cytoplasmic expression of UGT2B17 is ~90–100% in (a), ~75% in (b), ~20–30% in (c) and ~5–10% in (d, e). Nuclear expression of UGT2B17 is ~90% in (d) and ~30% in (e). A tumour lacking UGT2B17 cytoplasmic and nuclear staining is depicted in (f). Basal and stromal cells were devoid of staining. Black arrows show positive nuclear expression, orange arrows show nuclear and cytoplasmic expression. In e and f, blue arrows show negative nuclear and cytoplasmic UGT2B17 expression.

Back to article page